<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002945</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000065406</org_study_id>
    <secondary_id>RPCI-DS-96-48</secondary_id>
    <nct_id>NCT00002945</nct_id>
  </id_info>
  <brief_title>High Dose Chemotherapy, Peripheral Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Acute Myeloid Leukemia</brief_title>
  <official_title>High-Dose Cytarabine and Idarubicin Induction, High Dose Etoposide and Cyclophosphamide Intensification, Autologous Stem Cell Transplantation and Interleukin-2 Immune Modulation in Previously Untreated De Novo and Secondary Adult Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roswell Park Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Roswell Park Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
      so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation
      may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells.
      Interleukin-2 may stimulate a person's white blood cells to kill leukemia cells.

      PURPOSE: Phase III trial to study the effectiveness of high-dose combination chemotherapy,
      peripheral stem cell transplantation, and interleukin-2 in treating patients who have acute
      myeloid leukemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine relapse free survival of patients with previously untreated de novo or
           secondary acute myeloid leukemia treated with high dose cytarabine and idarubicin
           induction, high dose etoposide and cyclophosphamide intensification, filgrastim (G-CSF),
           melphalan, radiotherapy, autologous peripheral blood stem cell (PBSC) transplantation,
           and interleukin-2.

        -  Correlate remission rate and relapse free survival with multidrug resistance phenotype
           in patients treated with this regimen.

        -  Determine stem cell content and presence of cells with leukemia specific markers in PBSC
           harvested following high dose etoposide and cyclophosphamide intensification.

        -  Correlate NK cell expansion (an increase in both proportion and absolute number) during
           interleukin-2 therapy following autologous PBSC transplantation with disease free
           survival.

      OUTLINE:

      Induction

        -  Patients receive cytarabine IV over 1 hour every 12 hours for 6 days and idarubicin IV
           over 30 minutes following third, fifth, and seventh doses of cytarabine. Beginning 12
           hours after the last dose of cytarabine, patients receive filgrastim (G-CSF)
           subcutaneously (SQ) each day until blood counts recover.

      Intensification

        -  Patients receive etoposide IV over 34.3 hours followed 1 hour later by cyclophosphamide
           IV over 2 hours for 3 days. Beginning 24 hours after the last dose of cyclophosphamide,
           patients receive G-CSF SQ each day until blood counts recover.

      Peripheral blood stem cells (PBSC) are harvested and selected for CD34+ cells. Patients
      receive melphalan IV over 1 hour on day -4 followed by total body irradiation on days -3, -2,
      and -1. PBSC are reinfused on day 0.

      When blood counts recover, patients receive high dose interleukin-2 SQ on days 1-10 followed
      by low dose interleukin-2 SQ on days 11-13. Interleukin-2 treatment repeats every 14 days for
      6 courses in the absence of disease progression or unacceptable toxicity. Patients with
      immunologic response to 6 courses of interleukin-2 treatment may continue for 6 additional
      courses.

      PROJECTED ACCRUAL: Approximately 100 patients will be accrued for this study over 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 1996</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2001</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the efficacy of 4-6 h and 18-24 h, 20% ALA applications on superficial and nodular epidermally-derived lesions using ca633 nm laser irradiation.</measure>
    <time_frame>24 hours</time_frame>
    <description>To determine the efficacy of 4-6 h and 18-24 h, 20% ALA applications on superficial and nodular epidermally-derived lesions using ca633 nm laser irradiation.</description>
  </primary_outcome>
  <enrollment type="Actual">61</enrollment>
  <condition>Leukemia</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aldesleukin</intervention_name>
    <description>IV</description>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <description>IV</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>IV</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
    <description>IV</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
    <description>IV</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>idarubicin</intervention_name>
    <description>IV</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
    <description>IV</description>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
    <description>IV</description>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <description>delivered to the cancer cells</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically proven de novo or secondary acute myeloid leukemia with a
             classification of M0-M2 or M4-M7

               -  No classification of M3

               -  No promyelocytic leukemia

          -  Prior medical conditions allowed:

               -  Myelodysplastic syndromes

               -  Aplastic anemia

               -  Paroxysmal nocturnal hemoglobinuria

               -  Myeloproliferative disorders except Philadelphia chromosome positive chronic
                  myelogenous leukemia

        PATIENT CHARACTERISTICS:

        Age:

          -  Over 25

        Performance status:

          -  Not specified

        Life expectancy:

          -  At least 4 weeks

        Hematopoietic:

          -  Not specified

        Hepatic:

          -  Bilirubin no greater than 2 times normal

          -  SGOT no greater than 2 times normal

          -  Alkaline phosphatase no greater than 2 times normal

        Renal:

          -  Creatinine no greater than 1.5 times normal

        Cardiovascular:

          -  Ejection fraction at least 45%

          -  No severe cardiovascular disease including myocardial infarction within past 6 months,
             uncontrolled symptomatic congestive heart failure, angina pectoris, or multifocal
             cardiac arrhythmias

        Other:

          -  No uncontrolled diabetes mellitus

          -  No other active malignancy

          -  No hypersensitivity to E. coli derived drug preparations

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  No prior chemotherapy for acute leukemia except hydroxyurea

          -  Prior chemotherapy allowed for other malignancy or other medical condition

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  Prior radiotherapy allowed for other malignancy or other medical condition

        Surgery:

          -  Not specified
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Meir Wetzler, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Roswell Park Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>April 15, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2003</study_first_posted>
  <last_update_submitted>April 12, 2012</last_update_submitted>
  <last_update_submitted_qc>April 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 13, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>untreated adult acute myeloid leukemia</keyword>
  <keyword>adult acute monoblastic leukemia and acute monocytic leukemia (M5)</keyword>
  <keyword>adult acute erythroid leukemia (M6)</keyword>
  <keyword>adult acute myeloblastic leukemia without maturation (M1)</keyword>
  <keyword>adult acute myeloblastic leukemia with maturation (M2)</keyword>
  <keyword>adult acute myelomonocytic leukemia (M4)</keyword>
  <keyword>adult acute megakaryoblastic leukemia (M7)</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>adult acute minimally differentiated myeloid leukemia (M0)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Aldesleukin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Interleukin-2</mesh_term>
    <mesh_term>Idarubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

